79
Participants
Start Date
August 31, 2021
Primary Completion Date
January 17, 2024
Study Completion Date
December 12, 2024
Mirvetuximab soravtansine
Administered by intravenous (IV) infusion on Day 1 of every 3-week cycle
Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma
Royal North Shore Hospital, St Leonards
Newcastle Private Hospital, New Lambton Heights
UZ Leuven, Leuven
Cabrini Hospital Malvern, Malvern
Monash Health, Clayton
CHU UCL, Namur
Burnside War Memorial Hospital - The Brian Fricker Oncology Centre, Toorak Gardens
St John of God Subiaco Hospital, Subiaco
Institut Català d' Oncologia L' Hospitalet, Barcelona
UZ Gent, Ghent
Complejo Hospitalario Provincial de Castellón, Castelló
Institut Poali Calmette, Marseille
Hospital Reina Sofia, Córdoba
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
IRCCS - Istituto Europeo di Oncologia, Milan
Virginia Cancer Specialists, PC, Gainesville
Centre CARIO - HPCA, Plérin
Hospital Universitario HU de Jaen, Jaén
Virginia Oncology Associates, Norfolk
Duke University, Durham
ClÃ-nica Universidad de Navarra (CUN), Pamplona
Hospital MD Anderson Cancer Center Madrid, Madrid
Hospital de San Chinarro-Clara Campal, Madrid
Florida Cancer Specialists - Panhandle, Tallahassee
University of Miami, Miami
Florida Cancer Specialist East Division, West Palm Beach
Florida Cancer Specialist North Division, St. Petersburg
Florida Cancer Specialists - South, Fort Myers
The University of Alabama at Birmingham - Division of Gynecology Oncology O'Neal Comprehensive Cancer Center, Birmingham
Tennessee Oncology / Sarah Cannon Research Institute, Nashville
Azienda Ospedaliero-Universitaria-IRCCS, Bologna
Virgen del Rocío, Seville
Zangmeister Cancer Center / Sarah Cannon Research Institute, Columbus
Cleveland Clinic Fairview Hospital-Moll Cancer Center, Cleveland
Hillcrest Hospital: North Campus, Mayfield Heights
Cleveland Clinic Foundation, Cleveland
ICO Centre Rene Gauducheau, Saint-Herblain
Azienda Unita Sanitaria Locale di Ravenna, Ravenna
Centre Oscar Lambret, Lille
Washington University School of Medicine, St Louis
Institut de Cancerologie Strabsourg Europe Unité de recherche clinique, Strasbourg
Centre Hospitalier Lyon Sud, Pierre-Bénite
Centre Léon Bérard, Lyon
Women's Cancer Center, Covington
OU Health Stephenson Cancer Center, Oklahoma City
Groupe Hospitalier Diaconesse, Croix Saint-Simon, Paris
Texas Oncology - Dallas Presbyterian, Dallas
Texas Oncology, The Woodlands
Texas Oncology-South Austin, Austin
University of Colorado School of Medicine, Aurora
Istituto Nazionale Tumori Napoli, Napoli
Arizona Oncology Associates, PC - HOPE, Tucson
UCLA-JCCC Dept of OBGYN - Women's Health Clinical Research Unit, Los Angeles
City of Hope, Duarte
Osperdale Cannizzaro di Catania, Catania
Northwest Cancer Specialist, P.C., Portland
Willamette Valley Cancer Institute and Research Center, Eugene
Kadlec Clinic Hematology & Oncology, Kennewick
Alaska Women's Cancer Care/Providence Alaska Medical Center, Anchorage
Yale University School of Medicine, New Haven
Maine Medical Partners - Women's Health, Scarborough
Tufts Medical Center, Boston
Baystate Medical Center, Springfield
Holy Name Medical Center, Teaneck
Women & Infants Hospital of Rhode Island Oncology Research, Providence
Princess Margaret Cancer Centre - University Health Network, Toronto
McGill University Health Center, Montreal
Ciussse-Chus, Sherbrooke
Bon Secours Hospital, Cork
St James's Hospital, Dublin
Beaumont Hospital, Dublin
Mater Misericordiae University Hospital, Dublin
Hospital La Paz, Madrid
Hospital Clinico, Valencia
University Hospital Waterford, Waterford
Institut Català d'Oncologia - Hospital Universitari Germans Trias i Pujol, Unidad de Investigación Clínica, Servicio de Oncología, Institut Josep Carreres (IJC, 1ª planta), Badalona
Vall d'Hebron Institute of Oncology, Barcelona
Lead Sponsor
AbbVie
INDUSTRY